Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1120
http://purl.obolibrary.org/obo/NCIT_C1120
|
|---|---|
| Preferred Name | Halofuginone |
| Definitions |
An orally-active quinazolinone alkaloid with potential antineoplastic activity. Halofuginone interferes with the signaling pathway of transforming growth factor beta (TGF beta) and inhibits expression of matrix metalloproteinase 2, thereby inhibiting collagen type I synthesis and inducing extracellular matrix degradation, resulting in inhibition of angiogenesis, tumor growth, or metastasis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally-active quinazolinone alkaloid with potential antineoplastic activity. Halofuginone interferes with the signaling pathway of transforming growth factor beta (TGF beta) and inhibits expression of matrix metalloproteinase 2, thereby inhibiting collagen type I synthesis and inducing extracellular matrix degradation, resulting in inhibition of angiogenesis, tumor growth, or metastasis. |
|---|---|
| prefLabel | Halofuginone
|
| label | Halofuginone
|
| Has_Salt_Form | |
| code | C1120
|
| Has_Target | |
| prefixIRI | NCIT:C1120
|
| in_subset | |
| Preferred_Name | Halofuginone
|
| FDA_UNII_Code | L31MM1385E
|
| Contributing_Source | FDA
|
| Chemical_Formula | C16H17BrClN3O3
|
| Maps_To | Halofuginone
|
| CAS_Registry | 55837-20-2
|
| Legacy Concept Name | Halofuginone
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0062095
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |